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BACKGROUND:  33 
The adherence profile of HIV-infected patients predicts the therapeutic outcome, in particular 34 
during the early phase of antiretroviral therapy (ART). 35 
 36 
METHODS:  37 
We conducted a prospective observational multicenter trial monitoring adherence, virological 38 
and immunological parameters over the initial 6 months of treatment. Thirty-five subjects 39 
were starting a treatment regimen including atazanavir, ritonavir and emtricitabine-tenofovir. 40 
Adherence was assessed using self-completed questionnaires, announced pill counts and the 41 
medication event monitoring system (MEMS®) for each drug. Three MEMS measures were 42 
defined: the percentages of doses taken, days with the correct dosing and doses taken on time 43 
(+/-3 hours). Dynamic virological suppression (DVS) was defined as a reduction in the 44 
plasma HIV-RNA level of >1 log10 per month or < 40 copies/mL. 45 
 46 
RESULTS:  47 
The cumulative treatment time was 5,526 days. A high level of adherence was observed. The 48 
MEMS-defined adherence for correct dosing (-0.68% per 4-week, p < 0.03) and timing 49 
compliance (-1.60% per 4-week, p < 0.003) decreased significantly over time. The MEMS-50 
defined adherence data were concordant with the pill counts along the trial, but not with the 51 
data from the questionnaires. The median [range] percentages of doses taken (100% [50-52 
102]), days with the correct dosing (95% [41-100]) and doses taken on time (86% [32-100]) 53 
were significantly associated with DVS in separate models. Among these three measures, the 54 
percentage of doses taken on time had the greatest ability to predict DVS.    55 
 56 
CONCLUSION: Timing compliance should be supported to optimize DVS during the early 57 
phase of treatment by once-daily boosted protease inhibitor-based ART. 58 
 59 
TRIAL REGISTRATION: Clinical trial NCT00528060 60 
61 
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Introduction 62 
Adherence is a strong predictor of the virological response (1-3) and the survival (4, 5) 63 
of HIV-infected patients. Therefore, improving adherence has been an area of intense research 64 
among patients receiving antiretroviral therapy (ART). Efforts have focused on interventions 65 
aimed at changing patient behavior (6) and on improving treatment characteristics, leading to 66 
the simplification of treatment (7). Adherence to ART has generally been reported as the 67 
average number of doses taken divided by the prescribed doses during a defined period of 68 
observation (8). The two major limits of this analytical approach are (i) that it does not 69 
account for the dynamics of adherence (9) and (ii) that it does not account for the drug intake 70 
pattern (10). Depending on the ART class in terms of the pharmacokinetic profile, antiviral 71 
potency (11-13) and phase of treatment (14), different patterns of adherence have been 72 
associated with different virological outcomes. For example, the average adherence to boosted 73 
protease inhibitors (PI) was found to be closely associated with the virological outcome (12, 74 
15). Whether strict inter-dose timing is required for virological suppression is not known. 75 
Moreover, the ability to consider measurements of adherence to one drug as a surrogate for 76 
adherence to all drugs is speculative. The simultaneous intake of several individual 77 
components of combination ART is also required for optimal efficacy. Selective drug intake 78 
can lead to periods of single or dual agent exposure. There has been inconsistent data 79 
regarding the frequency of differential adherence (16, 17), which has been shown to be 80 
associated with virological failure and drug resistance (18).  81 
Another challenge is the method used to assess adherence to prescribed ART (19, 20). 82 
Although there is no gold standard, electronic monitoring appears to be the most reliable 83 
method to record dose timing in the research setting (19, 20).   84 
The objectives of this work were to assess the concordance between different 85 
adherence measurement methods and to describe the dynamics of adherence to a newly 86 
initiated ART regimen. Medication Event Monitoring System caps were used to assess the 87 
simultaneity of drug taking. We identified adherence factors that correlated with virological 88 
suppression during the first 6 months of an antiretroviral regimen consisting of ritonavir-89 
boosted atazanavir (ATV/RTV) combined with tenofovir/emtricitabine (Truvada, TVD) in 90 
antiretroviral-naive participants enrolled in the ANRS 134-COPHAR 3 trial.  91 
 92 
 93 
 94 
 95 
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Methods 96 
Study design and population 97 
The ANRS 134-COPHAR 3 trial was a multicenter prospective study conducted on HIV-1-98 
infected treatment-naive patients starting a PI-containing ART regimen consisting of 300 mg 99 
of atazanavir (2 capsules of 150 mg) boosted with 100 mg ritonavir (1 soft capsule) and a 100 
fixed dose combination of two co-formulated nucleoside analogs: tenofovir disoproxil 101 
fumarate (300 mg) and emtricitabine (200 mg). Thirty-five patients were included and were 102 
followed for 24 weeks. The trial enrolled HIV-1-infected subjects from the outpatient clinics 103 
of 14 French university and general hospitals and was completed between February and 104 
November 2008. All patients‟ viruses were demonstrated to be sensitive to each component of 105 
the therapy using a genotypic resistance assay prior to inclusion of the patients in the study. 106 
The study was performed according to the Declaration of Helsinki and its amendments and 107 
was approved by the Ethics Committee of Ile de France VII (Le Kremlin-Bicêtre, France), 108 
which applies for all centers according to the French law. All subjects provided written 109 
informed consent. The EUDRA CT number is 2007-003203-12, and the protocol has been 110 
registered under the identifier NCT00528060 (Clinicaltrials.gov). The patients were evaluated 111 
at baseline and during five subsequent visits at weeks (W) 4, W8, W12, W16 and W24. The 112 
laboratory data were collected as part of routine clinical care and included the plasma HIV-113 
RNA level (lower limit of quantification, <40 cp/mL), the CD4 cell count and safety 114 
parameters (creatinine clearance, bilirubinemia and liver enzyme levels, assessed according to 115 
the ANRS scale to grade the severity of adverse events: 116 
http://www.anrs.fr/index.php/content/download/2242/12805/file/ANRS-GradeEI-V1-En-117 
2008.pdf ).  118 
 119 
Measurements of patient adherence to the ART regimen 120 
We used three methods to assess adherence. First, a pharmacist performed a monthly 121 
announced pill count for each ART component. Second, self-reported adherence was 122 
measured using the ANRS adherence questionnaire (9) at W4, W16 and W24. Briefly, the 123 
questionnaire asked subjects to report the number of missed doses during a 4-day period, the 124 
last week end and a 4-week period to detect subjects with < 95% adherence. Third, the 125 
adherence was prospectively monitored using three Medication Event Monitoring System 126 
caps (MEMS®; AARDEX Group, Switzerland), one for each bottle containing atazanavir 127 
capsules, ritonavir soft-capsules or tenofovir/emtricitabine fixed dose regimen tablets. The 128 
patients and physicians were not aware of the dosing history data compiled using the MEMS 129 
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caps during the study. Each bottle containing antiretroviral drugs was filled by the pharmacist 130 
who delivered the drugs monthly to the pharmacy hospital during refill. The MEMS caps 131 
monitored the exact time and date of the opening of each pill bottle. We summarized the 132 
adherence as (1) the taking compliance (corresponding to the number of openings divided by 133 
the number of prescribed doses), (2) correct dosing (corresponding to the number of days with 134 
openings performed as prescribed divided by the number of monitored days) and (3) the 135 
timing compliance (corresponding to the number of openings +/- 3 hours from the dosing 136 
prescription divided by the number of prescribed doses). The simultaneity of the drug intake 137 
was evaluated based on the delays between MEMS cap openings. Because we found high 138 
levels of simultaneity, we averaged the adherence of the 3 MEMS caps for the subsequent 139 
analyses. Finally, we assessed the self-reported impact of MEMS use on convenience and 140 
adherence at the end of the trial. 141 
 142 
Virological outcomes 143 
The cross-sectional virological success was defined at three different time points according to 144 
the French guidelines  145 
(http://www.sante.gouv.fr/IMG/pdf/Rapport_2010_sur_la_prise_en_charge_medicale_des_pe146 
rsonnes_infectees_par_le_VIH_sous_la_direction_du_Pr-_Patrick_Yeni.pdf) as follows: an 147 
HIV-RNA reduction of > 2 log10 at W4, a viral load < 400 cp/mL at W12 and a viral load < 148 
40 cp/mL at W24.  149 
To assess the relationship between MEMS-defined adherence and virological suppression, we 150 
defined dynamic virological suppression (DVS), which takes into account the dynamics of 151 
both adherence and viral decline following ART initiation. DVS was evaluated at the end of 152 
each of five time periods (W0-W4, W4-W8, W8-W12, W12-W16 and W16-W24) and was 153 
defined as an HIV-RNA level reduction of > 1 log10 per 4-week period (3) or a level < 40 154 
copies/mL. The ends of the periods corresponded to the times at which HIV-RNA 155 
measurements were performed as part of the ANRS 134-COPHAR 3 trial. 156 
 157 
Statistical analysis 158 
The sample size was defined for the pharmacokinetic analysis of atazanavir with ritonavir 159 
(21). The categorical variables were summarized using percentages, and continuous variables, 160 
such as adherence, were summarized using medians and ranges. The agreement between the 161 
methods for discriminating adherence > 95% during similar periods was calculated using 162 
Cohen‟s Kappa coefficient. The longitudinal data with repeated measurements were analyzed 163 
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using generalized linear mixed models (22, 23). For the continuous outcomes, such as 164 
adherence, we used the MIXED procedure in SAS with the same 5 periods defined for DVS. 165 
To analyze DVS, which is a discrete binary variable, we used the GLIMMIX procedure in 166 
SAS. The abilities of several separate models to predict DVS using the MEMS-defined 167 
adherence measurements (percentages of doses taken, days with correct dosing and doses 168 
taken on time) were assessed by the area under the Receiver Operating Characteristic (ROC) 169 
curve. In addition, a cut-off for adherence that can predict DVS was explored by computing 170 
the sensitivity, specificity and Youden J index in R (package „pROC‟: http://cran.r-171 
project.org/web/packages/pROC/pROC.pdf). The analyses were conducted with SAS 172 
software V 9.2 (SAS institute, Cary, NC), and a p-value < 0.05 was considered statistically 173 
significant. 174 
 175 
 176 
Results 177 
Baseline characteristics, efficacy and tolerance  178 
Thirty-five subjects were included in the study. Their baseline characteristics are shown in 179 
Table 1. The median age was 36 years [range: 24 to 66], and 83% of the patients were male. 180 
At enrollment, 9% of the patients had a clinical AIDS-defining event. The median CD4 count 181 
was 280 cells/µL [111 to 461], and the median HIV-RNA level was 4.4 log10 cp/mL [2.0 to 182 
5.6].  183 
The therapeutic outcomes are shown in Figure 1. Twenty-three patients (66%) had decreases 184 
in the HIV-RNA level of > 2 log at W4, 32 patients (94%) had an HIV-RNA level < 400 185 
cp/mL at W12 and 30 patients (86%) had HIV-RNA level < 40 cp/mL at W24 (the remaining 186 
patients had levels of 45, 47, 59, 72 and 154 cp/mL). The median CD4 cell count increased 187 
from 280 at W0 to 369 at W4 and 436 cells/µL at W24. One out of the 25 patients with a 188 
baseline HIV-RNA level < 100,000 cp/mL had a W24 HIV-RNA level > 40 cp/mL, and 4/10 189 
patients with a baseline HIV-RNA level > 100,000 cp/mL had a W24 HIV-RNA level > 40 190 
cp/mL (p < 0.02 by Fisher‟s exact test). None of the adherence measures was significantly 191 
associated with virological success in the cross-sectional analyses (35 patients) at W4, W12 192 
and W24. 193 
The median bilirubinemia increased from 9 μM/L [range: 2 to 19] at W0 to 39 μM/L [range: 4 194 
to 181] at W4 and 42 μM/L [range: 8 to 101] at W24. Creatinine clearance was stable over 195 
time. Two severe adverse events occurred. One patient had a grade 4 hyperbilirubinemia at 196 
W8 (195 µmol/L; 11 times the normal value). The treatment regimen was discontinued, and 197 
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RTV was stopped. At W16, this patient‟s bilirubinemia decreased to 75 µmol/L. Another 198 
patient had transient hepatitis with an elevated ALAT level (421 IU/L; 9 times the normal 199 
value, corresponding to Grade 3) at W8 without recurrence after the same treatment was 200 
resumed at W10. 201 
 202 
Adherence measures and agreement between methods 203 
Overall, 5,526 days were monitored. The results of the three methods used to assess 204 
adherence are shown in Table 2. At W4, the results for MEMS-defined adherence > 95% 205 
exhibited an excellent agreement with the results for pill count-defined adherence > 95% 206 
(Kappa=0.8, 95% confidence interval [0.5 to 1.0]) but poor agreement with the self-reported 207 
results form the questionnaires (Kappa=0.0, 95% confidence interval [-0.1 to 0.2]). The 208 
concordance results between the adherence measures were lower at W16 or W24.  209 
The MEMS-defined adherence levels for percentages of doses taken, days with correct dosing 210 
and doses taken on time over time are presented in Figure 2A. The percentage adherence 211 
decreased significantly over time for days with correct dosing (-0.68% per 4-week, p < 0.03) 212 
and doses taken on time (-1.60% per 4-week, p < 0.003) but did not significantly decrease for 213 
percentages of doses taken (-0.44% per 4-week, p=0.10). For 70 days (1.3%), only 1 or 2 214 
MEMS openings were recorded per day, and for 204 days (3.7%), there were no recorded 215 
openings. Among the 5,252 remaining days with 3 MEMS openings, 5,225 (99.5%) days had 216 
the 3 openings performed within 30 minutes.  217 
 218 
Relationship between adherence and dynamic virological suppression 219 
The numbers of patients achieving dynamic virologic suppression (DVS) per period were 220 
35/35 for W0-W4, 18/35 for W4-W8, 20/35 for W8-W12, 27/35 for W12-W16 and 30/35 for 221 
W16-W24. The numbers of patients for whom MEMS data were available for each period 222 
were 34/35 for W0-W4, 33/35 for W4-W8, 32/35 for W8-W12, 33/35 for W12-W16 and 223 
30/35 for W16-W24.  In the longitudinal analysis (162 observations in 35 patients), the 224 
percentages of doses taken (Odds Ratio, 1.7; 95% confidence interval [1.1 to 2.9]; p=0.04), 225 
days with correct dosing (Odds Ratio, 1.6; 95% confidence interval [1.1 to 2.5]; p=0.03) and 226 
doses taken on time (Odds Ratio, 1.4; 95% confidence interval [1.1 to 1.8]; p=0.02) were 227 
significantly associated with DVS in separate models. Figure 2B depicts the ROC curves 228 
corresponding to the 3 MEMS adherence measures. The timing compliance had a greater 229 
discriminatory value for DVS than percentages of doses taken and days with correct dosing, 230 
with an area under the curve of 0.68. The timing compliance cut-off that maximized the 231 
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sensitivity and specificity to predict a > 1 log10 reduction in the HIV-RNA level over 4 weeks 232 
or an HIV-RNA level < 40 cp/mL at any time was 78%. 233 
 234 
Self-reported questionnaires on the use of MEMS 235 
Twenty-nine out of the 30 patients who responded to the questionnaire reported that the use of 236 
MEMS was easy. Nine reported that they felt they were being spied on. None reported that 237 
MEMS use affected the patient-physician relationship. No modification of drug-taking 238 
behavior was reported by 16 of the 30 patients (53%), whereas the remaining patients reported 239 
that MEMS helped them to maintain better adherence to their regimens (4/30, sometimes, and 240 
10/30, frequently).    241 
 242 
 243 
Discussion 244 
Our data show that a once-daily multiple-tablet regimen consisting of ritonavir-boosted 245 
atazanavir in combination with tenofovir/emtricitabine for the initial treatment of 246 
antiretroviral-naive HIV-1-infected patients was associated with a high adherence level, a 247 
high simultaneous drug intake and an excellent rate of virological response over the first 24 248 
weeks of treatment. This observation should be interpreted in the context of a clinical trial 249 
together with intensive monitoring. Despite this high overall level of adherence, we were able 250 
to demonstrate significant associations between virological response and the average 251 
adherence (particularly timing compliance) during the 4-week period preceding the 252 
virological evaluation.  253 
Self-reported adherence questionnaires generally tend to overestimate adherence (24). In our 254 
study, more patients were classified as <95% adherent with questionnaires compared with 255 
MEMS or pill count. This might be due to the stringent algorithm we used to classify self-256 
reported adherence in the questionnaire and the difference between perceived adherence and 257 
objective adherence. Bilirubin level, which is more objective,, has been linked to adherence to 258 
atazanavir (25, 26). Of note, our dataset served for external validation of the use of bilirubin 259 
level to detect sub-optimal atazanavir exposure, as reported elsewhere (27). Nevertheless, the 260 
bilirubin normogram and therapeutic drug monitoring of atazanavir concentrations had lower 261 
predictive power to detect past non-adherence episodes. In addition, only MEMS can provide 262 
a reliable history of timing compliance. Consistent with previous studies, the MEMS data 263 
exhibited strong agreement with the pharmacy adherence data (28). Gross et al. reported a 264 
lower overall MEMS-defined taking compliance of 84% during the first 4-month period of 265 
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antiretroviral therapy with nelfinavir (3). The differences between our study and the study of 266 
Gross et al. could be explained by differences in a better tolerance profile or simpler dosing 267 
for the ATV/RTV plus TVD QD regimen. Other alternative explanations for high adherence 268 
levels are selection bias and the Hawthorne effect. The volunteers, who agreed to use the 269 
MEMS caps and to undergo more frequent blood sampling to participate in the clinical trial, 270 
may be more likely to adhere. In turn, such intensive monitoring may also support and sustain 271 
high adherence levels, as shown in a prior intervention study using MEMS (29) and in the 272 
qualitative evaluation of the MEMS in our study. The virological success rate reported in this 273 
trial (91% of HIV-RNA levels <50 cp/mL at W24) outperformed the results of the CASTLE 274 
study (70% of HIV-RNA levels <50 cp/mL at W24), one of the largest trial to evaluate the 275 
use of ATV/RTV and TVD by treatment-naive HIV-infected patients (30). Of note, contrary 276 
to the CASTLE study, all our patients were assessed for treatment drug resistance, and we 277 
planned to exclude patients with resistance mutations to any drug in the combined regimen.  278 
Although it has been suggested that newer potent antiretroviral combinations are effective at 279 
moderate levels of adherence (17, 31, 32), we found herein a significant association between 280 
average adherence and dynamic virological suppression in the context of high levels of 281 
adherence. The dose timing has been previously reported as an important factor to achieve 282 
virological success with antiretroviral therapy (33, 34). The added value of incorporating dose 283 
timing errors has received less scrutiny. In a previous study (21), the use of MEMS-defined 284 
dosing data halved the unexplained variability in ATV clearance. Of note, the use of timing 285 
compliance improved our ability to predict insufficient DVS relative to the use of the 286 
percentages of doses taken and days with correct dosing (Figure 2B), with an optimized 287 
predictive value at the timing compliance cut-off of 78%. This result might be specific to the 288 
short half-life of ATV/RTV (mean, 7 to 10 hours), which requires regular inter-dose intervals 289 
for the drug concentration to remain within the therapeutic range. In addition, timing 290 
compliance may be more relevant for atazanavir and tenofovir due to the food effect, which 291 
enhances bioavailability and reduces pharmacokinetic variability (35). We hypothesized that 292 
the variability in the ATV pharmacokinetics related to timing compliance (21) also influenced 293 
DVS among treatment-naive HIV-infected subjects starting antiretroviral therapy, 294 
strengthening the link between pharmacokinetics and pharmacodynamics. 295 
The level of simultaneity in taking drugs was rather good, in accordance with the results of a 296 
previous study (16) but in contrast to the results of Shuter et al., who found 47% of the 297 
patients staggered at least once the doses of ritonavir (36).   298 
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Adherence declined over time. Gross et al. (3) reported that there is a 1-month “honeymoon” 299 
period after treatment initiation before the adherence rate begins to decline. In our study, the 300 
dose timing and correct dosing were more affected by pill burden fatigue than the taking 301 
compliance was in the context of a QD 4-pill regimen. This result supports the 302 
recommendation to that QD ATV/RTV and TVD be taken at a regular time every day during 303 
the early stage of treatment. Whether this statement remains valid for the maintenance phase, 304 
once virological suppression has been achieved, is unknown, however. 305 
None of the adherence measures was significantly associated with the milestone of cross-306 
sectional virological success at W4, W12 and W24 as defined in international guidelines. The 307 
statistical power for this analysis was limited, while our 35 patients showed a high adherence 308 
levels. Interestingly and counter-intuitively, the percentage of virological success increased 309 
between W4 and W12, while MEMS-defined adherence decreased after the first month.  310 
 311 
We are aware of the limitations in this study. First, the sample size was rather small as it was 312 
defined for the pharmacokinetics analysis of atazanavir with ritonavir (21). We took 313 
advantage of the dynamics of both virological suppression and adherence to study several 314 
periods per subject. We were able to increase the power of the longitudinal analysis of the 315 
DVS compared to the cross-sectional analysis of virological success. Nevertheless, we could 316 
not adjust for confounding variables when predicting the virological outcome. Second, the 317 
follow-up was limited to 6 months, even though the use of antiretroviral therapy is life long. 318 
However, the effect of non-adherence seems to wane over time, and the first 6 months are 319 
therefore critical. Third, our study population had a relatively good immuno-virological status 320 
at the start of the study, and both the potency and the pharmacological characteristics of 321 
recent antiretroviral drugs have improved in the last decade. These improvements have led to 322 
the development of simpler regimens that are easier to adhere to and have led to more robust 323 
virological effects. Patients are also being treated sooner than previously, and all these factors 324 
result in improved treatment efficacy. Fourth, because our study population had a high overall 325 
adherence level, gaps in medications were infrequent. In addition, treatment gaps and the 326 
coefficient of variation in dose timing are strongly correlated (37). Therefore, we were unable 327 
to incorporate such gaps as a factor. Finally, our results cannot be extrapolated to treatment-328 
experienced subjects who initiate a new ART regimen or to the use of other antiretroviral 329 
combinations by treatment-naive patients. For example, ART drugs with longer half-lives, 330 
such as non-nucleoside reverse transcriptase inhibitors, may be less susceptible to irregular 331 
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dose timing (31), underscoring the importance of studying adherence patterns separately for 332 
each antiretroviral regimen. 333 
Our results may have important implications for clinical practice and future research. In the 334 
modern antiretroviral era, the role of adherence goes beyond achieving an undetectable 335 
plasma viral load at a predetermined time point (38). New paradigms have emerged, such as 336 
treatment as prevention (39), maximal virological suppression to reduce immune activation 337 
(40) and the control of HIV replication in viral reservoirs, such as the central nervous system 338 
(41) and the genital tract (42). Our study assessed the use of electronic devices to monitor and 339 
support high sustained adherence levels because adherence is crucial for improving 340 
virological outcomes at the start of antiretroviral therapy. It showed that such devices are easy 341 
to use and are well accepted by patients. 342 
 343 
Although current guidelines for improving adherence to antiretroviral treatment (43) 344 
acknowledge the importance of treatment simplification to once-a-day regimens and fixed 345 
dose regimens consisting of one pill per day, there is no explicit recommendation for taking 346 
doses at regular time intervals. Here, we found that a once-daily 4-pill-per-day regimen was 347 
associated with excellent adherence, excellent simultaneity of drug intake and high rates of 348 
viral suppression . In the context of treatment-naive HIV-infected subjects starting once-daily 349 
ATV/RTV and TVD combination, our findings suggest that timing compliance predicts the 350 
viral suppression outcome better than other average adherence measures. 351 
352 
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 382 
Table and Figure Legends: 383 
 384 
Table 1. Baseline characteristics of the 35 patients included in the ANRS 134 COPHAR-3 385 
trial  386 
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Table 2. Adherence > 95% according to different measures and for different periods and the 387 
concordance with the MEMS data 388 
 389 
Figure 1. Changes in the HIV-RNA level and CD4 cell count during the ANRS 134-Cophar 3 390 
trial (n=35). The error bars represent the standard deviations.   391 
Figure 2. Boxplots of the MEMS-defined percentages of doses taken, days with correct dosing 392 
and doses taken on time (Panel A, the error bars represent 1.5 time the interquartile range), 393 
and their abilities to predict dynamic virological suppression (Panel B). 394 
 395 
396 
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      397 
Table  1. 398 
 399 
Characteristics  
Age, median [range]  36 [24 - 66] 
Male, n (%) 29 (83) 
High school, n (%) 30 (86) 
Smoker, n (%) 12 (35) 
Alcohol >4 times/week, n (%) 4 (12) 
Cannabis during the last year, n (%) 7 (21) 
Infection via sexual intercourse, n (%) 34 (97) 
AIDS, n (%)  3 (9) 
Creatinine clearance, mL/min   
       median [range] 104.8 [52.4 - 177.6] 
Total bilirubinemia, µmol/L  
       median [range] 9 [3-21] 
HIV-RNA level, cp/mL  
       median [range], log10 4.4 [2.0 - 5.7] 
       >100,000, n (%) 10 (29) 
CD4 cells/mm3  
      median [range],  280 [111 - 461] 
      <200, n (%) 5 (14) 
AIDS: Acquired Immunodeficiency Syndrome, which refers to Category C clinical condition of the CDC 400 
Classification System 1993 401 
402 
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 Table 2. 403 
 404 
 405 
406 
 Total 
Adherence<95%  
n (%) 
Kappa 
with MEMS (95% CI) 
W0-W4    
Pharmacy pill count 34 4 (12) 0.8 (0.5 to 1.0) 
Questionnaire 35 7 (20) 0.0 (-0.1 to 0.2) 
MEMS 34 6 (18) NA 
    
W12-W16    
Pharmacy pill count 33 3 (9) 0.4 (0.1 to 0.7) 
Questionnaire 33 12 (36) -0.3 (-0.6 to 0.0) 
MEMS 33 9 (27) NA 
    
W20-W24    
Pharmacy pill count 31 10 (32) 0.6 (0.3 to 0.9) 
Questionnaire 35 14 (40) -0.2 (-0.4 to 0.1) 
MEMS 33 8 (24) NA 
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